Celldex Therapeutics, Inc. (CLDX)
| Market Cap | 1.07B |
| Revenue (ttm) | 5.37M |
| Net Income (ttm) | -63.69M |
| Shares Out | 39.61M |
| EPS (ttm) | -2.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 11 |
| Last Price | $26.77 |
| Previous Close | $26.49 |
| Change ($) | 0.28 |
| Change (%) | 1.06% |
| Day's Open | 25.47 |
| Day's Range | 23.95 - 27.61 |
| Day's Volume | 288,389 |
| 52-Week Range | 2.20 - 33.23 |
Celldex (CLDX) delivered earnings and revenue surprises of -31.25% and -39.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
HAMPTON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.
HAMPTON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the presentation of promising data from the Company's growing bispecific platform at the Americ...
Not at its present valuation, it's not.
HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020.
The biotech reported interim results from a phase 1b study.
--CDX-0159 generally well tolerated to date-- --Conference call to be held at 7:45 a.m. ET today-- HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today repor...
HAMPTON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company's participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conf...
Celldex Therapeutics Inc (NASDAQ: CLDX) will expand the clinical development of CDX-0159 into prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pr...
--Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation-- --Potential to e...
HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healt...
Celldex Therapeutics is a biopharmaceutical company focused on developing monoclonal and bispecific antibody-based therapeutics. Celldex's new pipeline is now made up of 3 Phase 1 immunotherapies/target...
Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.
HAMPTON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel, effective...
These stocks have made investors richer by posting explosive revenue growth or advancing significantly in high-impact programs.
HAMPTON, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact urticaria...
HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx C...
-- A gonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated-- --Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -...
Celldex (CLDX) delivered earnings and revenue surprises of -5.88% and 130.35%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020.
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's why shares of these drugmakers seem unstoppable this year.
Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.
HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind ...
Why Celldex Has Been A Big Winner In 2020
Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.
HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global Healthcare C...
Here we discuss five biotech companies recording impressive growth so far in 2020.
HAMPTON, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients with advanc...
Celldex Therapeutics' (CLDX) CEO Anthony Marucci on Q2 2020 Results - Earnings Call Transcript
--Conference Call and Webcast today at 4:30pm ET-- --Conference Call and Webcast today at 4:30pm ET--
HAMPTON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial markets...
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for July 9th
As of late, it has definitely been a great time to be an investor in Celldex Therapeutics, Inc. (CLDX).
Here's what pushed up shares of the highest-flying healthcare stocks.
The market is reacting to large stock purchases from inside and outside the company.
HAMPTON, N.J., June 18, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614 s...
HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public off...
Celldex Jumps On CDX-0159 Data
HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to market condi...
Celldex Therapeutics Inc (NASDAQ:CLDX) was trading 3% higher from the previous closing price.
Shares of Celldex Therapeutics Inc (NASDAQ:CLDX) moved higher by 1.5% from the previous closing price.
Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.
--Data strongly support expanding development into mast cell driven diseases----Data presented in a late-breaking session at EAACI Annual Congress 2020-- HAMPTON, N.J., June 06, 2020 (GLOBE NEWSWIRE) ...
Is (CLDX) Outperforming Other Medical Stocks This Year?
Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Celldex also eligible to receive future milestone payments plus royalties Celldex also eligible to receive future milestone payments plus royalties
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock?
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response... [Read more...]
| Industry Biotechnology | IPO Date Mar 10, 2008 |
| CEO Anthony Marucci | Employees 123 |
| Stock Exchange NASDAQ | Ticker Symbol CLDX |
Financial Performance
In 2020, CLDX's revenue was $7.42 million, an increase of 107.61% compared to the previous year's $3.57 million. Losses were -$59.78 million, 17.5% more than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price forecast is 34.67, which is an increase of 29.51% from the latest price.